Sanctuary Advisors LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 17,515 shares of the medical device company’s stock, valued at approximately $490,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in ATRC. Geneos Wealth Management Inc. bought a new stake in AtriCure during the second quarter worth $37,000. Smartleaf Asset Management LLC grew its holdings in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Harbor Investment Advisory LLC acquired a new position in AtriCure in the 2nd quarter valued at approximately $40,000. Allworth Financial LP bought a new position in AtriCure during the 2nd quarter worth $43,000. Finally, Fifth Third Bancorp acquired a new stake in AtriCure during the 1st quarter valued at approximately $51,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Director Karen Prange sold 3,564 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the transaction, the director owned 22,809 shares of the company’s stock, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider directly owned 86,511 shares in the company, valued at $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 53,616 shares of company stock valued at $2,149,994 in the last three months. 4.00% of the stock is owned by corporate insiders.
AtriCure Price Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. Piper Sandler lifted their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.89.
Check Out Our Latest Analysis on ATRC
AtriCure Company Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Read More
- Five stocks we like better than AtriCure
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
